Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Xeris Biopharma Holdings, Inc. Common Stock

XERS

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Last trade $16.77
Day change +$0.07 (+0.42%)
Day range $16.40 – $16.91
Volume 1,103,455
Market cap $3.05B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.05B
Price / earnings
—
Price / book
62.54×
Price / sales
8.29×
EV / sales
8.44×
EV / EBITDA
52.76×

Profitability

Earnings per share
-$0.04
Return on assets
-1.53%
Return on equity
-13.32%
Dividend yield
0%

Liquidity and leverage

Debt / equity
3.89×
Current ratio
2.15×
Quick ratio
1.58×
Cash ratio
0.97×

Cash flow

Price / cash flow
41.43×
Price / free cash flow
42.01×
Free cash flow
$72.62M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XERS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$107.23M$92.1M$83.13M$85.81M$74.38M$71.54M$60.12M$60.1M
Cost of revenue$12.43M$12.51M$10.57M$10.95M$11M$11.9M$8.73M$9.48M
Gross profit$94.8M$79.59M$72.55M$74.86M$63.38M$59.64M$51.39M$50.62M
Selling, general and administrative$64.11M$61.04M$53.14M$47.5M$46.46M$44.39M$44.02M$40.14M
Research and development$11.06M$10.67M$8.78M$7.87M$7.48M$8.06M$7.75M$6.09M
Total operating expenses$77.88M$74.42M$64.64M$58.09M$56.65M$55.16M$54.48M$48.94M
Operating income$16.92M$5.17M$7.92M$16.77M$6.73M$4.48M-$3.09M$1.68M
Interest expense-$6.46M-$6.95M-$6.88M-$7.15M-$7.27M-$7.36M-$7.31M-$5.01M
Income before taxes$11.29M-$31.1M$2.23M$11.08M$621K-$1.93M-$9.22M-$5.11M
Income taxes$0$0$0$0$0$0$0$0
Net income$11.29M-$31.1M$2.23M$11.08M$621K-$1.93M-$9.22M-$5.11M
Net income attributable to common shareholders$11.29M-$31.1M$2.23M$11.08M$621K-$1.93M-$9.22M-$5.11M
EBITDA$19.95M$8.21M$10.96M$19.82M$9.78M$7.52M-$65K$4.7M
Basic earnings per share$0.06-$0.18$0.01$0.07$0.00-$0.01-$0.06-$0.03
Diluted earnings per share$0.06-$0.18$0.01$0.06$0.00-$0.01-$0.06-$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Xeris (XERS) Q2 Revenue Jumps 49%

Xeris Biopharma reported strong Q2 2025 financial results, with revenue jumping 48.8% year-over-year to $71.5 million, driven by significant growth in Recorlev sales. The company raised its full-year revenue guidance and showed a positive turn in adjusted EBITDA.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.